CPSE:NSIS BChemicals
Assessing Novozymes (CPSE:NSIS B) Valuation After Solid Q1 2026 Earnings Release
Q1 earnings as the key trigger
Novozymes (CPSE:NSIS B) is back in focus after reporting first quarter 2026 results, with sales of €1,119.3 million and net income of €199.1 million compared with the same period a year earlier.
See our latest analysis for Novozymes.
The Q1 release appears to have steadied sentiment, with a 1-day share price return of 2.25% partly offsetting weaker recent momentum, including a 1-year total shareholder return of 12.68% and a 5-year total shareholder return of...